Compare Stocks: HSGX, STTK, ALLO, and SGMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.73 -7.0%	$1.97	$1.04 ▼ $4.46	$642.61M	0.47	4.75 million shs	7.26 million shs
HSGX Histogenics	$1.86 +6.9%	$1.33	$0.08 ▼ $1.43	$175.95M	3.1	9.06 million shs	4.66 million shs
SGMT Sagimet Biosciences	$10.86 +1.4%	$8.87	$4.50 ▼ $11.27	$665.72M	3.45	1.12 million shs	1.25 million shs
STTK Shattuck Labs	$6.33 -2.6%	$7.14	$1.68 ▼ $8.33	$652.36M	1.09	712,365 shs	1.06 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-6.99%	-12.63%	-17.62%	-7.98%	+51.75%
HSGX Histogenics	0.00%	0.00%	0.00%	0.00%	+80.58%
SGMT Sagimet Biosciences	+1.40%	-1.18%	+13.48%	+68.90%	+57.62%
STTK Shattuck Labs	-2.62%	-8.39%	-11.34%	+51.44%	+214.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.73 -7.0%	$1.97	$1.04 ▼ $4.46	$642.61M	0.47	4.75 million shs	7.26 million shs
HSGX Histogenics	$1.86 +6.9%	$1.33	$0.08 ▼ $1.43	$175.95M	3.1	9.06 million shs	4.66 million shs
SGMT Sagimet Biosciences	$10.86 +1.4%	$8.87	$4.50 ▼ $11.27	$665.72M	3.45	1.12 million shs	1.25 million shs
STTK Shattuck Labs	$6.33 -2.6%	$7.14	$1.68 ▼ $8.33	$652.36M	1.09	712,365 shs	1.06 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-6.99%	-12.63%	-17.62%	-7.98%	+51.75%
HSGX Histogenics	0.00%	0.00%	0.00%	0.00%	+80.58%
SGMT Sagimet Biosciences	+1.40%	-1.18%	+13.48%	+68.90%	+57.62%
STTK Shattuck Labs	-2.62%	-8.39%	-11.34%	+51.44%	+214.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	379.77% Upside
HSGX Histogenics	0.00	N/A	N/A	N/A
SGMT Sagimet Biosciences	2.73	Moderate Buy	$27.96	157.45% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	101.86% Upside

Current Analyst Ratings Breakdown

Latest HSGX, STTK, ALLO, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$6.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$12.00 ➝ $29.00
8/12/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	29,884.89	N/A	N/A	$1.30 per share	1.33
HSGX Histogenics	N/A	N/A	N/A	N/A	($0.01) per share	N/A
SGMT Sagimet Biosciences	$2M	337.53	N/A	N/A	$3.42 per share	3.18
STTK Shattuck Labs	$1M	635.28	N/A	N/A	$1.30 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
HSGX Histogenics	-$8.64M	-$0.79	N/A	N/A	N/A	N/A	-34.96%	18.40%	N/A
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest HSGX, STTK, ALLO, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
HSGX Histogenics	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
HSGX Histogenics	N/A	4.05	4.05
SGMT Sagimet Biosciences	N/A	45.03	45.02
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
HSGX Histogenics	40.35%
SGMT Sagimet Biosciences	87.86%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
HSGX Histogenics	19.70%
SGMT Sagimet Biosciences	11.50%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	345.49 million	299.89 million	Optionable
HSGX Histogenics	49	94.60 million	N/A	Not Optionable
SGMT Sagimet Biosciences	8	62.16 million	55.01 million	Optionable
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable

HSGX, STTK, ALLO, and SGMT Headlines

Recent News About These Companies

Bank of America Corp DE Cuts Holdings in Shattuck Labs, Inc. $STTK

September 9 at 3:28 AM | marketbeat.com

Wellington Management Group LLP Makes New Investment in Shattuck Labs, Inc. $STTK

September 8 at 4:48 AM | marketbeat.com

3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.

September 7 at 4:00 AM | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of "Buy" by Analysts

September 5, 2026 | americanbankingnews.com

The Manufacturers Life Insurance Company Invests $1.58 Million in Shattuck Labs, Inc. $STTK

September 4, 2026 | marketbeat.com

BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK

September 3, 2026 | marketbeat.com

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Buy" from Brokerages

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK

August 30, 2026 | marketbeat.com

356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

August 28, 2026 | marketbeat.com

Raymond James Financial Upgrades Shattuck Labs (NASDAQ:STTK) to "Strong-Buy"

August 26, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Price Up 5.5% - Here's What Happened

August 24, 2026 | marketbeat.com

S&G Foundation Makes New $3.02 Million Investment in Shattuck Labs, Inc. $STTK

August 23, 2026 | marketbeat.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

August 13, 2026 | marketbeat.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HSGX, STTK, ALLO, and SGMT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.73 -0.13 (-6.99%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.03 (+2.02%)

As of 09/9/2026 07:44 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Histogenics NASDAQ:HSGX

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Sagimet Biosciences NASDAQ:SGMT

$10.86 +0.15 (+1.40%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$10.93 +0.07 (+0.64%)

As of 09/9/2026 07:35 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Shattuck Labs NASDAQ:STTK

$6.33 -0.17 (-2.62%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$6.34 +0.00 (+0.08%)

As of 09/9/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HSGX, STTK, ALLO, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HSGX, STTK, ALLO, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HSGX, STTK, ALLO, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HSGX, STTK, ALLO, and SGMT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Histogenics NASDAQ:HSGX

Sagimet Biosciences NASDAQ:SGMT

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HSGX, STTK, ALLO, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HSGX, STTK, ALLO, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HSGX, STTK, ALLO, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HSGX, STTK, ALLO, and SGMT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Histogenics NASDAQ:HSGX

Sagimet Biosciences NASDAQ:SGMT

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools